MRNA logo Moderna +
Moderna
+

Moderna (MRNA) Business News

Track Moderna in real time with a live news feed covering Moderna stock news, official press releases, company announcements, and an archive of historical Moderna news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
5:00 PM | Tuesday | May 12, 2026 Accesswire

Moderna Recognized by TIME as One of the World's Most Impactful Companies

News Thumbnail
5:15 PM | Wednesday | May 6, 2026 Accesswire

Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

News Thumbnail
6:30 AM | Friday | May 1, 2026 Accesswire

Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates

News Thumbnail
10:00 AM | Tuesday | Apr 21, 2026 Accesswire

Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting

News Thumbnail
9:40 AM | Tuesday | Apr 21, 2026 Accesswire

Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19

News Thumbnail
7:00 AM | Tuesday | Apr 21, 2026 Accesswire

Moderna to Present at Upcoming Conferences in May 2026

News Thumbnail
3:00 PM | Friday | Apr 17, 2026 Accesswire

Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting

News Thumbnail
7:00 AM | Wednesday | Apr 15, 2026 Accesswire

Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026

News Thumbnail
4:15 PM | Tuesday | Mar 3, 2026 GlobeNewsWire

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

News Thumbnail
4:15 PM | Tuesday | Mar 3, 2026 GlobeNewsWire

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

News Thumbnail

Moderna Recognized by TIME as One of the World's Most Impactful Companies

Accesswire

5:00 PM | Tuesday | May 12, 2026

news photo
Loading...

CAMBRIDGE, MA / ACCESS Newswire / May 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked no. 1 on TIME's 2026 list of the World's Most Impactful Companies.

Read full article redirect
5:00 PM | Tuesday | May 12, 2026

Moderna Recognized by TIME as One of the World's Most Impactful Companies

Accesswire

CAMBRIDGE, MA / ACCESS Newswire / May 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked no. 1 on TIME's 2026 list of the World's Most Impactful Companies.

Read full article arrow
News Thumbnail
5:15 PM | Wednesday | May 6, 2026

Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

Accesswire

Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to begin in 2026 CAMBRIDGE, MA / ACCESS Newswire / May 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced a publication in the New England Journal of Medicine of the positive Phase 3 study results evaluating mRNA-1010, its vaccine candidate for seasonal influenza. The peer-reviewed article summarizes the safety and efficacy data from Moderna's Phase 3 study (P304) evaluating the relative vaccine efficacy (rVE) of mRNA-1010 against influenza illness compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older.

Read full article arrow
News Thumbnail
6:30 AM | Friday | May 1, 2026

Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates

Accesswire

Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international markets Reports first quarter GAAP net loss of $(1.3) billion and GAAP EPS of $(3.40), including $0.9 billion non-recurring litigation settlement charge Reiterates plan to deliver up to 10% revenue growth and GAAP operating expense reductions in 2026, excluding the non-recurring litigation settlement charge Advanced infectious disease portfolio with key regulatory milestones in the EU, including approval of mNEXSPIKE and mCOMBRIAX, Moderna's flu plus COVID combination vaccine Initiated Phase 3 clinical study evaluating intismeran autogene as monotherapy and in combination with KEYTRUDA QLEX for treatment of high-risk Stage 1 non-small cell lung cancer CAMBRIDGE, MA / ACCESS Newswire / May 1, 2026 / Moderna, Inc.
(NASDAQ:MRNA) today reported financial results and provided business updates for the... Read more

Read full article arrow
News Thumbnail
10:00 AM | Tuesday | Apr 21, 2026

Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting

Accesswire

Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29 - June 2 in Chicago, IL. The presentation details are as follows: Oral Presentation: Abstract #9500: Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 studySession Type/Title: Oral Abstract Session - Melanoma/Skin CancersData & Time: June 1, 8:00 AM - 11:00 AM CTPresenter: Matteo S.

Read full article arrow
News Thumbnail
9:40 AM | Tuesday | Apr 21, 2026

Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19

Accesswire

mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized product mCOMBRIAX will be made available in the European Union, subject to national regulatory and access procedures CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for mCOMBRIAX® (mRNA-1083), the Company's mRNA combination vaccine for active immunization for the prevention of influenza disease and COVID-19 caused by SARS-CoV-2 in individuals 50 years of age and older. This marketing authorization follows the positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) and is valid in all 27 European Union member states, as well as Iceland, Liechtenstein and Norway.

Read full article arrow
News Thumbnail
7:00 AM | Tuesday | Apr 21, 2026

Moderna to Present at Upcoming Conferences in May 2026

Accesswire

CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: BofA Securities 2026 Healthcare Conference, on Tuesday, May 12th at 11:20am PT RBC 2026 Global Healthcare Conference, on Tuesday, May 19th at 10:00 am ET Bernstein's 42nd Annual Strategic Decisions Conference, Thursday, May 28th at 10:00am ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.

Read full article arrow
News Thumbnail
3:00 PM | Friday | Apr 17, 2026

Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting

Accesswire

The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ (TPS> 1%) CAMBRIDGE, MA / ACCESS Newswire / April 17, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present data from a Phase 1/2 study of mRNA-4359, an investigational cancer antigen therapy, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, on April 17-22, 2026. The presentation reports safety, efficacy and translational data from a Phase 2 dose-expansion cohort of the Phase 1/2 study (NCT05533697), which evaluated mRNA-4359 + pembrolizumab as a first-line therapy in patients with locally advanced or metastatic melanoma.

Read full article arrow
News Thumbnail
7:00 AM | Wednesday | Apr 15, 2026

Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026

Accesswire

CAMBRIDGE, MA / ACCESS Newswire / April 15, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, May 1,2026 to report its first quarter 2026 financial results, and provide a corporate update.

Read full article arrow
News Thumbnail
4:15 PM | Tuesday | Mar 3, 2026

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

GlobeNewsWire

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industry Settlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the case Genevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Genevant/Arbutus patents and Moderna products, ending all patent-infringement litigation against Moderna arising from its unauthorized use of the technology in its COVID-19 vaccines Pfizer/BioNTech litigation... Read more

Read full article arrow
News Thumbnail
4:15 PM | Tuesday | Mar 3, 2026

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

GlobeNewsWire

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industry Settlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the case Genevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Genevant/Arbutus patents and Moderna products, ending all patent-infringement litigation against Moderna arising from its unauthorized use of the technology in its COVID-19 vaccines Pfizer/BioNTech litigation... Read more

Read full article arrow
News Thumbnail